Ascendis Pharma A/S announced its financial results for the first quarter ended March 31, 2025, reporting total revenue of €101.0 million, an increase from €95.9 million in the same period of 2024. This growth was primarily driven by product revenue, including €44.7 million from YORVIPATH following its commercial launch and €51.3 million from SKYTROFA.
The company reported a net loss of €94.6 million, or €1.58 per share, an improvement from a net loss of €131.0 million, or €2.30 per share, in Q1 2024. Research and development costs increased to €86.6 million, partly due to an impairment charge related to property, plant and equipment. Selling, general, and administrative expenses also rose to €101.0 million, driven by global commercial expansion activities for YORVIPATH and an impairment charge.
Ascendis Pharma ended the quarter with €518 million in cash and cash equivalents. The company reiterated its expectation for 2025 to be an inflection point with growing revenue and a clear path to cashflow breakeven in the near term. The TransCon CNP NDA was submitted in Q1 2025, with the MAA submission planned for Q3 2025, and topline COACH combination trial data is expected in Q2 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.